搜索结果
靶点ID:TCMBANKGE006691
靶点别名:ACH; CD333; CEK2; HSFGFR3EX; JTK4
靶点描述:fibroblast growth factor receptor 3
染色体:4
染色体位置:4p16.3
靶点类型:protein-coding
HERB_ID:-
HGNC_Link:3690
OMIM_Link:134934
Ensembl_Link:ENSG00000068078
靶点对应的植物
| ID | 拉丁名 | 药名 | 药用植物名 | 功能与主治 | 来源 | 药用部位 | 使用民族 |
|---|
靶点对应的化合物
| 化合物ID | 化合物名 | 别名 | 分子式 | 分子质量 | Smiles |
|---|
| TCMBANKIN016721 | phorbol diester | CCCC(=O)OC1C(C2(C(C=C(CC3(C2C=C(C3=O)C)O)CO)C4C1(C4(C)C)OC(=O)CCC)O)C | |||
| TCMBANKIN021186 | hexitol | Allitol; ZINC03831017; InChI=1/C6H14O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3-12H,1-2H; 488-44-8; (2R,3R,4S,5S)-hexane-1,2,3,4,5,6-hexol; GALACTITOL (D) | C6H14O6 | 182.17 | C(C(C(C(C(CO)O)O)O)O)O |
| TCMBANKIN037721 | Jasminoidin | C17H24O10 | 388.366 | C1(C(=O)OC([H])([H])[H])=C([H])O[C@@]([H])(O[C@@]2([H])[C@]([H])(O[H])[C@@]([H])(O[H])[C@]([H])(O[H])[C@@]([H])(C([H])([H])O[H])O2)[C@]([H])(C(C([H])([H])O[H])=C([H])C3([H])[H])[C@@]13[H] | |
| TCMBANKIN038938 | Bisindolylpyrrole CPB-53-594-6 | ||||
| TCMBANKIN040323 | Auxin A | 328.4 g/mol | |||
| TCMBANKIN057919 | 2(R)-(3,4-dimethoxy-phenyl)-propanel,3-diol-l-O-β-D-glucopyranoside | formic acid;fatty acids;FMT;saturated fatty acids;formicacid; methanol peroxide; Dioxirane-3-ol;251364_SIAL; 64-18-6; 27001_RIEDEL; HCOOH; Kyselina mravenci [Czech]; methoic acid; 06473_FLUKA; Spirit of formic acid; Formira; CBX; RCRA waste no. U123; Formylic acid; Methanoic acid; 09676_FLUKA; Formic acid (natural); C1 acid; CCRIS 6039; 49897_FLUKA; 7056-83-9; Kwas metaniowy [Polish]; Bilorin; Myrmicyl; RCRA waste number U123; Ameisensaeure [German]; F0507_SIAL; Collo-didax; EINECS 200-579-1; UN1779; C00058; Add-F; InChI=1/CH2O2/c2-1-3/h1H,(H,2,3; 33015_RIEDEL; 82069-14-5; H-COOH; Collo-bueglatt; LMFA01010040; 94318_FLUKA; AI3-24237; Wonderbond Hardener M 600L; HSDB 1646; Mierenzuur [Dutch]; formic acid; 06450_FLUKA; Sybest; Formic acid solution; FEMA No. 2487; Formisoton; CHEBI:30751; Ameisensaeure; 399388_SIAL; ST5214364; 8006-93-7; Ameisensaure; Formate standard for IC; CARBOXY GROUP; LS-1540; Methanoic acid monomer; Formic acid [UN1779] [Corrosive]; W248703_ALDRICH; Acide formique [French]; Aminic acid; Acido formico [Italian]; 06460_FLUKA; 15907-03-6; Hydrogen carboxylic acid; EPA Pesticide Chemical Code 214900; 56302_FLUKA | HCOOH or CH2O2 | 46.025 g/mol;46.03 | C(=O)O |
| TCMBANKIN057980 | l-alpha,gamma-diaminobutyric acid | H-Dab-OH; L-2,4-diaminobutyrate; PDSP2_000140; HY-101414; L-DABA; AmbotzHAA1224; Butanoic acid, 2,4-diamino-, (2S)-; L-2,4-Diaminobutanoate; C-09303; AC1Q5QMH; L-alpha,gamma-Diaminobutyric acid; AKOS017344502; (2S)-2,4-diaminobutanoic acid; CCG-36519; (S)-2,4-diamino-Butanoate; NCIStruc1_000167; 1758-80-1; 2,4-Diaminobutyrate; alpha,gamma-Diaminobutyrate; BDBM92987; ZINC52986906; DB03817; AN-49841; (S)-2,4-Diaminobutanoic acid; NCGC00013478; EN300-119052; UNII-92V7KM11ZK component OGNSCSPNOLGXSM-VKHMYHEASA-N; UNII-61HPH2F0W7; L-2,4-diamino-Butyric acid; OGNSCSPNOLGXSM-VKHMYHEASA-N; L-diaminobutyric acid; CHEMBL321357; (S)-2,4-diamino-Butanoic acid; NCIStruc2_000050; NCI41117; PDSP1_000141; MolPort-008-267-988; NSC-41117; AC1L34P9; CHEBI:48950; L-Dbu; Butanoic acid, 2,4-diamino-, (S)-; 61HPH2F0W7; CC-29888; L-2,4-diaminobutyric acid; 83D096; L-2, 4-diaminobutyric acid; L-2,4-Diamino-n-butyric acid; Diaminobutyric acid, L-; (S)-2,4-Diaminobutyric acid; H-L-Dab-OH; C03283; AK170036; 2,4-Diaminobutanoate; NCGC00013478-02; FCH833652; L-2,4-diaminobutanoic acid; NCGC00096593-01; SCHEMBL34706; CS-6314; I14-15389; BD211196-6739-4CDA-8627-C1676AC86B43; l-α, γ-diaminobutyricacid | C4H10N2O2 | 118.13 g/mol | C(CN)C(C(=O)O)N |
| TCMBANKIN057984 | PG | ST5214535; 504-63-2; .beta.-Propylene glycol; PDO; C02457; InChI=1/C3H8O2/c4-2-1-3-5/h4-5H,1-3H; 2-Deoxyglycerol; .omega.-Propanediol; 1,3-Dihydroxypropane; BRN 0969155; Propane-1,3-diol; Trimethylene glycol; beta-Propylene glycol; CHEBI:16109; 2-(Hydroxymethyl)ethanol; 1,3-Propylenediol; 533734_ALDRICH; 81780_FLUKA; 1,3-PROPANDIOL; 4-01-00-02493 (Beilstein Handbook Reference); AI3-01851; NSC 65426; P50404_ALDRICH; 1,3-Propylene glycol; omega-Propanediol; EINECS 207-997-3; 1,3-Propanediol; ZINC01529437; NSC65426; 757125-93-2;1,3-propanediol | C3H8O2 | 76.09 | C(CO)CO |
| TCMBANKIN058057 | D-Chiro-Inositol | Chiro-inositol;mesoinositol; Myo-inositol; i-inositol; Inositol-c; scyllo-insitol; Inositol;KS-00001292; TR-022051; BG01505581; MFCD01321249; CTK1C5947; AKOS024318869; INOSITOL (D); Inositene; CHEBI:27374; D-(+)-chiro-Inositol; LT03328768; I-6500; 2H3; (1R,2R,3R,4S,5S,6s)-cyclohexane-1,2,3,4,5,6-hexaol; D07CPO; W-203081; NCGC00178580-01; ZINC103574430; Myoinositol; ZINC100019018; NSC-103959; SCHEMBL13114116; UNII-1VS4X81277; 12513-EP2292610A1; AKOS015912934; NSC25142; Inosite; (1R,2R,3R,4R,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; BG00909558; 1,2,3,4,5,6-Cyclohexanehexol, (cis,cis,cis,trans,cis,trans)- #; BG01505582; NSC-127230; AK307531; Inositol, cis-; NSC 8101; 643-12-9; CHEBI:23311; MolPort-001-785-905; NSC-404118; KB-296111; 12513-EP2316831A1; K572; MolPort-003-719-862; Inositol, chiro-; Inositol (VAN8C; Isoinositol; I14-47230; GTPL4645; s4530; EINECS 211-394-0; 1,2,3,4,5,6-HEXAHYDROXY-CYCLOHEXANE; CHEBI:22357; AK324051; Inositol [USAN:NF]; bmse000922; CDAISMWEOUEBRE-OQYPVSDDSA-N; DSSTox_RID_76890; NCGC00255362-01; 1VS4X81277; 1D-Chiro-inositol; chiro-inositol; BG01505565; 488-55-1; BG01505566; AKOS015960429; NSC103959; 576-63-6; SBI-0051369.P003; 1,2,4,5/3,6-cyclohexanehexol; I14-2742; 12513-EP2277880A1; AKOS015960633; J101.891D; A834712; Scyllitol; CHEBI:23927; KM0846; 1,2,3,4,5,6-Hexahydroxycyclohexane; Spectrum3_001053; HMS2091N13; MLS001332378; MolPort-001-742-552; NCIOpen2_008191; Cocositol; Phaseomannitol; Scyllite; myo-Inositol, 98% 100g; BSPBio_002606; KBio2_002075; FT-0693614; Inositol, United States Pharmacopeia (USP) Reference Standard; TR-017741; CCRIS 6745; STL453612; ZINC253837650; I0631; D03SHD; SCHEMBL6791918; 3635-EP2292088A1; AB00051982_13; CHEBI:17268; TR-022053; Iso-inositol; MFCD00077932; CTK8B3795; myo-Inositol, >=99%; GTPL4495; C19891; KSC225S4P; ZINC100073149; DSSTox_GSID_23146; MLS001335965; TL8004551; SMR000857319; bmse000102; AJ-26654; 887751-76-0; DB03106; UNII-9O6Y5O4P9W; 38876-99-2; myo-Inositol, BioUltra, >=99.5% (HPLC); Inositol, neo-; Matezodambose; 6R79WV4R10; I0040; Mesol; W-203392; NSC404118; 1,2,4/3,5,6-Cyclohexane-1,2,3,4,5,6-hexol; Rat antispectacled eye factor; Inositol FCC; 3635-EP2305682A1; 1,2,3,5/4,6-Cyclohexanehexol; BG01505593; cis-Inositol, >=98.0% (TLC); Tox21_302035; CDAISMWEOUEBRE-LOLGQZEGSA-N; 643-10-7; AKOS027327401; 1,2,4/3,5,6-Hexahydroxycyclohexane; 3635-EP2295417A1; CHEMBL278373; FT-0652045; 3635-EP2305677A1; 1,2,3,4,5,6-Cyclohexanehexol; Neo-inositol; (1s,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Q-201583; Hexahydroxycyclohexane; SCHEMBL187278; (1S,2S,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; CHEMBL1231671; EINECS 207-682-0; I14-47232; 1D-myo-Inositol; CHEMBL468154; SCHEMBL13058696; SC-18136; 3635-EP2280282A1; DB13178; 3635-EP2289886A1; Spectrum_001595; Inositol, Pharmaceutical Secondary Standard; Certified Reference Material; NSC-757076; AKOS006240678; I14-60538; 12513-EP2374790A1; CJ-23964; AK102790; UNII-63GQX5QW03; INS; 87-89-8; Scyllite (for the structural isomer scyllo-Inositol); 2os9; CHEMBL1222251; I14-47231; MLS001335966; (1R,2R,3S,4R,5r,6S)-cyclohexane-1,2,3,4,5,6-hexaol; alloinositol; ANW-43204; 4irx; KS-1420; Inositol (VAN); inositols; 4L6452S749; C06153; (1R,2R,3R,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inosital; ZINC100037751; AB0014290; MEGxp0_001817; (1r,2R,3S,4r,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; Inositol, myo-; ELND 005; 13719-EP2311831A1; cyclohexane-1,2,3,4,5,6-hexol; FT-0627237; AKOS015912905; KS-0000146H; (+)-Chiro-Inositol; AC1L1A9E; L-(-)-chiro-Inositol, 95%; (1R,2R,3R,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; myo-Inositol, BioReagent, suitable for cell culture, suitable for insect cell culture, suitable for plant cell culture; 3635-EP2305636A1; C06151; 12513-EP2292597A1; myo-Inositol, purum, >=98.0% (HPLC); Inositol, scyllo-; MFCD00799555; 12513-EP2298768A1; NSC-25142; 1,2,3/4,5,6-cyclohexanehexol; MFCD00799556; cis-1,2,4-trans-3,5,6-Cyclohexanehexol; ST24024704; Inositol, myo- (8CI); SCHEMBL13114115; GTPL4649; Bios I; M01914; ST50406013; NSC127230; FT-0632209; ZINC250615063; AC1Q2AJJ; SR-05000001655; Mesoinosite; Muscle sugar; ZINC102201844; 6917-35-7; myo-Inositol, European Pharmacopoeia (EP) Reference Standard; 3635-EP2308879A1; Insitolum; D-myo-Inositol, Cell Culture Grade; I0630; Spectrum4_001193; epi-Cyclohexanehexol; SCHEMBL187796; NSC-45517; CDAISMWEOUEBRE-GPIVLXJGSA-N; 488-54-0; CC-093; 40032-EP2298312A1; ZINC1530357; 13719-EP2308875A1; CHEBI:27987; AN-24133; epi-Inositol; (1r,2R,3R,4s,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; Pharmakon1600-01500352; CDAISMWEOUEBRE-GNIYUCBRSA-N; Tox21_111642; UNII-6R79WV4R10; 13719-EP2316836A1; SMR000857145; HMS2230N03; (1s,2s,3s,4s,5s,6s)-cyclohexane-1,2,3,4,5,6-hexol; mesoinositol; NCGC00159409-04; CHEBI:27372; CJ-05199; SCHEMBL6378921; AK115152; (1/4) inverted exclamation markIC; SCHEMBL491333; myo-Inositol, Vetec(TM) reagent grade, 99%; 3635-EP2275412A1; ELND005; NCGC00169828-01; I0632; EINECS 207-681-5; 3635-EP2295437A1; SCHEMBL14542470; MolPort-003-848-190; Muco-Inositol; D0Y4UQ; Epi-inositol, 98%; 1,2,3,4,5,6/0-cyclohexanetetrol; Mesovit; D-chiro-Inositol, >=98.0% (HPLC); TRA-0204644; 36190-90-6; NSC 25142; cis-Inositol; (1R,2R,3S,4R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; SCHEMBL12377889; cis-1,2,3,5-trans-4,6-Cyclohexanehexol; i-Inositol; L-Inositol; CHEBI:10642; 12513-EP2305825A1; Chiro-inositol, (-)-; Inositol, muco-; Quercinitol; M94176HJ2F; HY-B1411; SCHEMBL12711208; SCHEMBL13580047; CDAISMWEOUEBRE-CDRYSYESSA-N; scyllo-Cyclohexanehexol; ZINC101185827; Allo-inositol; Tox21_111642_1; HMS3373E05; 1,3,5/4,6-Cyclohexanehexol; EINECS 209-000-7; KS-1284; W-203168; 13719-EP2280010A2; Phaseomannite; EPIINOSITOL; (+)-Epi-Inositol; NSC45517; Inositol (NF); 6643AB; (1R,2R,3S,4S,5S,6S)-Cyclohexane-1,2,3,4,5,6-hexaol; SCHEMBL4748543; AK307315; 13719-EP2269977A2; 488-58-4; UNII-M94176HJ2F component CDAISMWEOUEBRE-LKPKBOIGSA-N; cis-1,3,5-trans-4,6-Cyclohexanehexol; SCHEMBL13114128; SCHEMBL6468882; UNII-587A93P465; scyllo-Inositol, >=98%; SMR000857320; D-chiro Inositol; AZD 103; SCHEMBL188237; SCHEMBL12411898; bmse000113; epi-Inositol, >=98.0% (HPLC); MLS001335967; 19030-27-4; AK307406; INOSITOL (L); KBio2_007211; Cyclohexane-1,2,3,4,5,6-hexaol; 41546-34-3; (1S,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; NSC8101; NSC-55551; 63GQX5QW03; (1R)-Cyclohexane-1r,2c,3t,4c,5t,6t-hexaol; myo -Inositol; ZINC306121118; D08DXZ; ST24049158; AX8234329; Inositol, epi-; TRA0065469; 551-72-4; 488-59-5; NSC55551; 1D7A27BF-6060-4FA9-AC46-3BD18DBA406E; 3635-EP2298312A1; Myoinosite; HMS2235M23; NSC-55552; Inositol [Nonspecific isomer]; A836375; SR-05000001655-5; myo-Inositol, SAJ special grade, >=99.0%; 13719-EP2298734A2; D-chiro-Inositol; HMS2235H05; AN-18118; (1S,2R,4R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; KBio3_001826; Inositol, meso-; ZINC103574467; AS-10616; CAS-87-89-8; Inositina; SCHEMBL959404; I0629; BG00909545; AmbotzGBB1246; EINECS 211-393-5; 1,3,5/2,4,6-cyclohexanehexol; EINECS 201-781-2; SCHEMBL5831; Meat sugar; neoinositol; 9O6Y5O4P9W; (-)-chiro-Inositol; 13719-EP2289891A2; AKOS015895894; 13719-EP2295437A1; (-)-Inositol; NSC55552; Cyclohexanehexol; Inosital (TN); Levoinositol; FT-0632208; BG01505583; cyclohexane-1R,2R,3S,4S,5R,6S-hexol; TL8004550; L-chiro-Inositol; Myo inositol; Spectrum5_000961; (1R,2S,3S,4R,5S,6r)-cyclohexane-1,2,3,4,5,6-hexol; myo-inositol; (1S,2R,4S)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; MFCD00272608; MLS001332377; D08079; SCHEMBL12371461; meso-Inositol; D-myo-Inositol; Cyclohexitol; ZINC100018867; 1,2,3,4/5,6-cyclohexanehexol; D-(+)-chiro-Inositol, 95%; (1R,2R,3S,4S,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; ACon1_002457; KBioGR_001885; NSC-8101; TR-019452; FT-0670357; AKOS015994742; ZINC100032893; NSC757076; CS-4782; allo-Inositol, 97%; AN-23658; Mesoinosit; KS-00000QA9; AKOS027320475; KBio2_004643; ZINC103574475; UNII-4L6452S749; SCHEMBL5969; ZINC100055570; 1,3,5/2,4,6-Hexahydroxycyclohexane; KS-000017FC; 3635-EP2298775A1; bmse000901; FCH1118762; NCGC00159409-03; R1Y9F3N15A; I14-101844; myo-Inositol, for microbiology, >=99.0%; I0633; Dambose; myo-Inositol, PharmaGrade, meets FCC testing specifications, Manufactured under appropriate controls for use as a raw material in pharma or biopharmaceutical production.; FT-0693444; 1-L-chiro-Inositol; (1r,2r,3r,4r,5r,6r)-cyclohexane-1,2,3,4,5,6-hexol; SR-05000001655-1; SCHEMBL188106; L-(-)-chiro-Inositol; L-myo-Inositol; 1,2,3,4,5,6-Cyclohexanehexaol; UNII-M94176HJ2F component CDAISMWEOUEBRE-SHFUYGGZSA-N; ZINC100513675; 173524-45-3; 643C129; NSC-55558; CCG-36096; Mouse antialopecia factor; FT-0632730; NSC55558; 8LQ63P85IC; I0628; MolPort-006-111-433; NCI60_041778; CDAISMWEOUEBRE-NIPYSYMMSA-N; KBioSS_002075; C00137; CBU; 220128F1-89BF-442D-AD6D-E6D1EA7BA625; UNII-R1Y9F3N15A; D0B1EY; 1,2,3,5-trans-4,6-Cyclohexanehexol, cis-; MolPort-003-933-930; 587A93P465; CHEBI:25492; NSC 404118; UNII-M94176HJ2F; MCULE-2727773046; J101.890F; HMS3369F20; SCHEMBL5832; UNII-8LQ63P85IC; 12513-EP2277881A1; UNII-4661D3JP8D; 53319-35-0; MLS001335968; 1,2,3,4,5,6-Cyclohexanehexol #; myo-Inositol, p.a., 98.0%; meso-(1/4) inverted exclamation mark (1/4); AC-11070; SCHEMBL959405; NCGC00178580-03; (1r,2R,3S,4s,5R,6S)-cyclohexane-1,2,3,4,5,6-hexol; I06-1350; 1L-Chiro-inositol; SCHEMBL1055883; Nucite; LS-2350; RP24128; 1,2,3,4,5/6-cyclohexanehexol; GTPL4648; Epitope ID:144993; SCHEMBL12735687; AKOS006332036; Inositol NF 12; MFCD00003863; AK546883; 1,2,4/3,5,6-cyclohexanehexol; 13719-EP2298775A1; EINECS 230-024-9; W-202862; (1R,2R,3S,4S,5S,6R)-CYCLOHEXANE-1,2,3,4,5,6-HEXOL; NCGC00159409-02; 4661D3JP8D; 1L-myo-Inositol; Scyllo-inositol; C06152; Chiro-inositol, (+)-; Inositol, i-; CHEMBL1950780; 1,2,3,4,5,6-cyclohexanhexol; 1,2,3,4,5,6-cyclohexanehexol, (1alpha,2alpha,3alpha,4beta,5alpha,6beta); D-(+)-Chiro Inositol; SC-91157; KS-00001315; NP-010162; I14-47229; VC30505; 4CH-024633; KB-251247; MFCD00065455; (1R,2R,3S,4R,5S,6S)-cyclohexane-1,2,3,4,5,6-hexol; CDAISMWEOUEBRE-UHFFFAOYSA-N; ZINC100024490; Inositol, allo-; AI3-16111; Ambap6917-35-7; HMS3369B06; 7B0CEF84-D9CE-4A88-AA7D-EC50C89387A5; 1,3,4,5,6-Cyclohexanehexol; inositol; W-202861; SCHEMBL187397; DSSTox_CID_3146; ZINC100035580; 40032-EP2311830A1; 12513-EP2298744A2; K-9876; INOSITOL, MESO; CHEBI:24848; bmse000103; TR-016439; SCHEMBL13207905; (+)-Inositol; CHEMBL122705;cocositol;D-myo-inositol | C6H12O6 | 180.16 g/mol | C1(C(C(C(C(C1O)O)O)O)O)O |
| TCMBANKIN058374 | Indolyl acetic acid | 3-indolylaceticacid;Indole acetic acid;IES;heteroauxin;1H-Indole-3-acetic acid (9CI); beta-Indoleacetic acid; 54692-39-6; I8262_SIGMA; CHEBI:16411; 87-51-4; 1H-indol-3-ylacetic acid; CCRIS 1014; Heteroauxin; InChI=1/C10H9NO2/c12-10(13)5-7-6-11-9-4-2-1-3-8(7)9/h1-4,6,11H,5H2,(H,12,13; 1H-Indole-3-acetic-a-t acid (9CI); EPA Pesticide Chemical Code 128915; EU-0099905; Indole-3-acetic acid-carboxy-14C; Acetic acid, indolyl-; beta-Indolylacetic acid; I3750_ALDRICH; omega-Skatole carboxylic acid; 2-(1H-Indol-3-yl)acetic acid; .beta.-Indole-3-acetic acid; MLS001066408; I2886_SIGMA; C00954; Hexteroauxin; .beta.-Indolylacetic acid; Indol-3-ylacetic acid; Rhizopin; Indole-3-acetic acid (8CI); [3H]-IAA; NSC 3787; Indole-3-acetic-t acid; WLN: T56 BMJ D1VQ; 3-(Carboxymethyl)indole; .alpha.-Indol-3-yl-acetic acid; 45533_RIEDEL; (1H-Indol-3-yl)acetic acid; ST5308201; .omega.-Skatole carboxylic acid; Maybridge1_006755; IAA; SDCCGMLS-0066204.P001; beta-IAA; Indoleacetic acid (VAN); 3-IAA; 3-Indolylacetic acid; 6305-45-9; Indolyl-3-acetic acid; 3-Indolylessigsaeure; Oprea1_602123; indole-3-acetic acid; IAC; Rhizopon A; Kyselina 3-indolyloctova [Czech]; 2-(3-Indolyl)acetic acid 3-(Carboxymethyl)-1H-indole; 1H-Indole-3-acetic acid; 3-Indolylmethylcarboxylic acid; .beta.-IAA; AIDS009893; SMR000471855; SR-01000596909-2; EINECS 201-748-2; 2-(1H-indol-3-yl)ethanoic acid; alpha-IAA; Heteroauxinhexteroauxiniaa; .alpha.-IAA; indoleacetic acid; 2-(indol-3-yl)ethanoic acid; 3-Indoleacetic acid; NSC3787; .beta.-Indoleacetic acid; AIDS-009893; AI3-24131 | C10H9NO2 | 175.18 g/mol | C1=CC=C2C(=C1)C(=CN2)CC(=O)O |
| TCMBANKIN059926 | (-)-gossypol | C30H30O8 | 518.6 g/mol | CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O | |
| TCMBANKIN060910 | cis-9-hexadecenoic acid | C16H30O2 | 254.41 g/mol | CCCCCCC=CCCCCCCCC(=O)O | |
| TCMBANKIN061038 | Gaidic acid | C16H30O2 | 254.41 g/mol | CCCCCCCCCCCCCC=CC(=O)O |
靶点对应的疾病
| 疾病ID | 疾病名 | MeSH名 | HPO名 | UMLS名 | 疾病类型 |
|---|
| TCMBANKDI000009 | Neoplasms | Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI000054 | Nervous System Diseases; Mental Disorders | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI000076 | Neoplasms | - | Neoplastic Process | group | |
| TCMBANKDI000078 | Neoplasms; Skin and Connective Tissue Diseases | Abnormality of the integument; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI000166 | - | - | Neoplastic Process | disease | |
| TCMBANKDI000372 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI000891 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI001064 | - | Growth abnormality | Finding | phenotype | |
| TCMBANKDI001097 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI001231 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI001279 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Cardiovascular Diseases | Abnormality of the nervous system; Abnormality of blood and blood-forming tissues; Abnormality of the cardiovascular system | Disease or Syndrome | disease | |
| TCMBANKDI002459 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI002490 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI002881 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI002902 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI002974 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI003101 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI003261 | - | Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI003353 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI003394 | Pathological Conditions, Signs and Symptoms | Abnormality of the nervous system | Sign or Symptom | phenotype | |
| TCMBANKDI003411 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI003657 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI003797 | Digestive System Diseases | Abnormality of the digestive system | Disease or Syndrome | group | |
| TCMBANKDI003879 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Male Urogenital Diseases; Endocrine System Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
| TCMBANKDI004054 | Pathological Conditions, Signs and Symptoms | - | Neoplastic Process | phenotype | |
| TCMBANKDI004145 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI004376 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | group | |
| TCMBANKDI004489 | - | Abnormality of the ear | Congenital Abnormality | disease | |
| TCMBANKDI004646 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI004904 | Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI005091 | Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI005528 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Nervous System Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI005587 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI005868 | - | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI006084 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI006121 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI006182 | - | Abnormality of limbs; Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI006249 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI006337 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI006852 | - | - | Congenital Abnormality | disease | |
| TCMBANKDI007091 | Neoplasms | - | Neoplastic Process | phenotype | |
| TCMBANKDI007737 | Pathological Conditions, Signs and Symptoms; Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI008017 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI008206 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Congenital Abnormality | group | |
| TCMBANKDI009057 | - | Growth abnormality | Finding | disease | |
| TCMBANKDI009422 | - | - | Finding | phenotype | |
| TCMBANKDI009935 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Nervous System Diseases | Abnormality of the nervous system | Congenital Abnormality | disease | |
| TCMBANKDI009951 | Nutritional and Metabolic Diseases; Musculoskeletal Diseases | Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI010203 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI010593 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI010675 | Chemically-Induced Disorders; Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI011000 | Pathological Conditions, Signs and Symptoms; Skin and Connective Tissue Diseases | Abnormality of the integument | Disease or Syndrome | disease | |
| TCMBANKDI011083 | Pathological Conditions, Signs and Symptoms | - | Sign or Symptom | group | |
| TCMBANKDI011167 | - | Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI011173 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI011402 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI011730 | Eye Diseases; Nervous System Diseases | Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI011743 | Neoplasms; Skin and Connective Tissue Diseases | Neoplasm; Abnormality of the breast | Neoplastic Process | group | |
| TCMBANKDI012074 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications | Abnormality of prenatal development or birth; Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI012178 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI012952 | - | Abnormality of the immune system; Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI013148 | Respiratory Tract Diseases; Nervous System Diseases | Abnormality of the nervous system; Abnormality of the respiratory system | Disease or Syndrome | disease | |
| TCMBANKDI013175 | - | - | Neoplastic Process | disease | |
| TCMBANKDI013341 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases; Neoplasms; Nutritional and Metabolic Diseases | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI013599 | - | Growth abnormality | Disease or Syndrome | phenotype | |
| TCMBANKDI013635 | - | Abnormality of limbs; Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI013839 | Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI013927 | Respiratory Tract Diseases | Abnormality of the respiratory system | Pathologic Function | phenotype | |
| TCMBANKDI014132 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI015356 | Skin and Connective Tissue Diseases | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI015420 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI015485 | Mental Disorders | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI016026 | Neoplasms; Eye Diseases | Neoplasm; Abnormality of the eye | Neoplastic Process | disease | |
| TCMBANKDI016214 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI016579 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI017024 | Neoplasms; Respiratory Tract Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI017577 | - | Abnormality of limbs; Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI017642 | Neoplasms | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI017770 | - | - | Disease or Syndrome | disease | |
| TCMBANKDI017776 | Pathological Conditions, Signs and Symptoms | - | Disease or Syndrome | disease | |
| TCMBANKDI017837 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI018090 | - | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI018117 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases; Otorhinolaryngologic Diseases | Abnormality of the ear | Disease or Syndrome | disease | |
| TCMBANKDI018481 | - | Abnormality of limbs; Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI018929 | Eye Diseases | Abnormality of the eye | Disease or Syndrome | disease | |
| TCMBANKDI018992 | Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI019155 | Pathological Conditions, Signs and Symptoms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system | Congenital Abnormality | disease | |
| TCMBANKDI019385 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Eye Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI019465 | Neoplasms; Male Urogenital Diseases; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | group | |
| TCMBANKDI019825 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI020119 | Mental Disorders | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI020129 | Skin and Connective Tissue Diseases | Abnormality of the integument; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI020138 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI020451 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI020602 | Male Urogenital Diseases | Abnormality of the genitourinary system | Disease or Syndrome | disease | |
| TCMBANKDI020864 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Digestive System Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI021387 | Nutritional and Metabolic Diseases | Abnormality of metabolism/homeostasis | Disease or Syndrome | phenotype | |
| TCMBANKDI021455 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI021622 | Mental Disorders | - | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI021924 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases; Endocrine System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI022173 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Musculoskeletal Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI022380 | Female Urogenital Diseases and Pregnancy Complications | Abnormality of prenatal development or birth | Pathologic Function | phenotype | |
| TCMBANKDI023185 | Pathological Conditions, Signs and Symptoms | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI023336 | Neoplasms | Abnormality of the endocrine system; Abnormality of the nervous system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI023361 | - | Abnormality of the nervous system | Finding | phenotype | |
| TCMBANKDI023464 | Nervous System Diseases | Abnormality of the nervous system | Disease or Syndrome | disease | |
| TCMBANKDI023751 | Pathological Conditions, Signs and Symptoms; Nervous System Diseases | Abnormality of the musculature | Finding | phenotype | |
| TCMBANKDI024262 | - | - | Neoplastic Process | phenotype | |
| TCMBANKDI024381 | Stomatognathic Diseases | Abnormality of head or neck | Anatomical Abnormality | disease | |
| TCMBANKDI024535 | Neoplasms; Respiratory Tract Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI024559 | - | Abnormality of head or neck | Finding | phenotype | |
| TCMBANKDI024668 | Musculoskeletal Diseases; Stomatognathic Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI024934 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Female Urogenital Diseases and Pregnancy Complications; Musculoskeletal Diseases | Abnormality of head or neck | Congenital Abnormality | group | |
| TCMBANKDI025171 | Otorhinolaryngologic Diseases | Abnormality of the immune system; Abnormality of the ear | Disease or Syndrome | disease | |
| TCMBANKDI025420 | Digestive System Diseases; Neoplasms | Abnormality of the digestive system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI025492 | Mental Disorders | - | Disease or Syndrome | group | |
| TCMBANKDI026459 | Neoplasms; Respiratory Tract Diseases; Otorhinolaryngologic Diseases | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI027026 | Neoplasms; Skin and Connective Tissue Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI027339 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | disease | |
| TCMBANKDI027401 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | - | Congenital Abnormality | disease | |
| TCMBANKDI027669 | - | - | Finding | phenotype | |
| TCMBANKDI027961 | Pathological Conditions, Signs and Symptoms; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nervous System Diseases | Abnormality of the nervous system | Congenital Abnormality | disease | |
| TCMBANKDI028095 | - | Abnormality of limbs; Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI028305 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI028400 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Nutritional and Metabolic Diseases; Skin and Connective Tissue Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI028468 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI028561 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI028747 | - | Abnormality of head or neck; Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI029306 | Neoplasms; Nervous System Diseases | - | Neoplastic Process | disease | |
| TCMBANKDI029520 | Mental Disorders | - | Mental or Behavioral Dysfunction | group | |
| TCMBANKDI029670 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Neoplasms; Nervous System Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI029799 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI029870 | - | Abnormality of head or neck; Abnormality of the skeletal system | Anatomical Abnormality | disease | |
| TCMBANKDI029899 | Neoplasms; Immune System Diseases; Hemic and Lymphatic Diseases | Neoplasm; Abnormality of blood and blood-forming tissues | Neoplastic Process | group | |
| TCMBANKDI030161 | - | Abnormality of head or neck | Anatomical Abnormality | disease | |
| TCMBANKDI030540 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Endocrine System Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI030607 | Musculoskeletal Diseases | - | Disease or Syndrome | disease | |
| TCMBANKDI030653 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI030837 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of limbs; Abnormality of the skeletal system | Congenital Abnormality | disease | |
| TCMBANKDI031083 | - | Abnormality of the skeletal system | Finding | phenotype | |
| TCMBANKDI031189 | Neoplasms | Neoplasm; Abnormality of the respiratory system | Neoplastic Process | disease | |
| TCMBANKDI031522 | Neoplasms; Female Urogenital Diseases and Pregnancy Complications; Male Urogenital Diseases | Abnormality of the genitourinary system; Neoplasm | Neoplastic Process | disease | |
| TCMBANKDI031570 | - | Abnormality of the nervous system | Mental or Behavioral Dysfunction | disease | |
| TCMBANKDI031671 | Neoplasms | - | Neoplastic Process | disease | |
| TCMBANKDI031802 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Musculoskeletal Diseases | Abnormality of head or neck; Abnormality of the skeletal system | Disease or Syndrome | disease | |
| TCMBANKDI032109 | Pathological Conditions, Signs and Symptoms | - | Disease or Syndrome | disease |
滇IICP备16009434号-1 |
Dai SX Lab